{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:30:17Z","timestamp":1777026617058,"version":"3.51.4"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T00:00:00Z","timestamp":1295913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>CMX001, a lipophilic nucleotide analog formed by covalently linking 3\u2011(hexdecyloxy)propan-1-ol to cidofovir (CDV), is being developed as a treatment for smallpox. CMX001 has dramatically increased potency versus CDV against all dsDNA viruses and, in contrast to CDV, is orally available and has shown no evidence of nephrotoxicity in healthy volunteers or severely ill transplant patients to date. Although smallpox has been eliminated from the environment, treatments are urgently being sought due to the risk of smallpox being used as a bioterrorism agent and for monkeypox virus, a zoonotic disease of Africa, and adverse reactions to smallpox virus vaccinations. In the absence of human cases of smallpox, new treatments must be tested for efficacy in animal models. Here we first review and discuss the rabbitpox virus (RPV) infection of New Zealand White rabbits as a model for smallpox to test the efficacy of CMX001 as a prophylactic and early disease antiviral. Our results should also be applicable to monkeypox virus infections and for treatment of adverse reactions to smallpox vaccination.<\/jats:p>","DOI":"10.3390\/v3020063","type":"journal-article","created":{"date-parts":[[2011,1,25]],"date-time":"2011-01-25T11:57:50Z","timestamp":1295956670000},"page":"63-82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans"],"prefix":"10.3390","volume":"3","author":[{"given":"Amanda D.","family":"Rice","sequence":"first","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew M.","family":"Adams","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Lampert","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway Suite, 340 Durham, NC 27713, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Foster","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway Suite, 340 Durham, NC 27713, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall","family":"Lanier","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway Suite, 340 Durham, NC 27713, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Robertson","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway Suite, 340 Durham, NC 27713, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Painter","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway Suite, 340 Durham, NC 27713, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard W.","family":"Moyer","sequence":"additional","affiliation":[{"name":"Department of Molecular Genetics and Microbiology, University of Florida, 1600 SW Archer Rd, Gainesville, FL 32610, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3201\/eid0403.980340","article-title":"Bioterrorism as a public health threat","volume":"4","author":"Henderson","year":"1998","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2105\/AJPH.91.12.1917-a","article-title":"Biopreparedness and public health","volume":"91","author":"Henderson","year":"2001","journal-title":"Am. J. Public Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/00000441-200206000-00004","article-title":"Viral agents as biological weapons and agents of bioterrorism","volume":"323","author":"Bronze","year":"2002","journal-title":"Am. J. Med. Sci."},{"key":"ref_4","unstructured":"Food and Drug Administration, HHS (2002). New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed. Regist., 67, 37988\u201337998."},{"key":"ref_5","unstructured":"Knipe, D.E., and Howley, P.M. (2001). Fields Virology, Lippincott Williams & Wilkins. [4th ed.]."},{"key":"ref_6","first-page":"505","article-title":"Eperimenteel onderzoek van Kon-. ijnensterfte door een filtreebaar virus","volume":"69","author":"Jansen","year":"1942","journal-title":"Tijdschr. Diergeneeskd."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000090790","article-title":"Genome-based phylogeny of poxvirus","volume":"49","author":"Xing","year":"2006","journal-title":"Intervirology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1099\/vir.0.19565-0","article-title":"Poxvirus genomes: A phylogenetic analysis","volume":"85","author":"Gubser","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_9","unstructured":"Fields, B.N., and Knipe, D.E. (1990). Virology, Raven Press. [2nd ed.]."},{"key":"ref_10","first-page":"2637","article-title":"Poxviridae: The viruses and their replication","volume":"Volume 2","author":"Fields","year":"1996","journal-title":"Fields Virology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-3527(08)00003-1","article-title":"Poxvirus host range genes","volume":"71","author":"Werden","year":"2008","journal-title":"Adv. Virus Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15787","DOI":"10.1073\/pnas.0609268104","article-title":"On the origin of smallpox: correlating variola phylogenics with historical smallpox records","volume":"104","author":"Li","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0042-6822(92)90445-U","article-title":"Restricted replication of ectromelia virus in cell culture correlates with mutations in virus-encoded host range gene","volume":"187","author":"Chen","year":"1992","journal-title":"Virology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0042-6822(90)90296-4","article-title":"Vaccinia virus host range genes","volume":"179","author":"Perkus","year":"1990","journal-title":"Virology"},{"key":"ref_15","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and Its Eradication, World Health Organization."},{"key":"ref_16","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and its Eradication, World Health Organization."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1099\/vir.0.81331-0","article-title":"Complete coding sequences of the rabbitpox virus genome","volume":"86","author":"Li","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.1700850102","article-title":"Rabbit pox: An experimental study of the pathways of infection in rabbits","volume":"85","author":"Bedson","year":"1963","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J.Virol."},{"key":"ref_20","first-page":"453","article-title":"Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies","volume":"47","author":"Westwood","year":"1966","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_21","first-page":"669","article-title":"An airborne outbreak of smallpox in a German hospital and its significance with respect to other recent outbreaks in Europe","volume":"43","author":"Wehrle","year":"1970","journal-title":"Bull. World Health Organ."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2008.03.005","article-title":"Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model","volume":"79","author":"Nalca","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1016\/j.vaccine.2009.06.105","article-title":"Evaluation of the efficacy of modified vaccinia Ankara (MVA)\/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model","volume":"27","author":"Garza","year":"2009","journal-title":"Vaccine"},{"key":"ref_24","unstructured":"(1996). FDA grants marketing clearance of Vistide for the treatment of CMV retinitis. AIDS Patient Care STDS, 10, 383\u2013384."},{"key":"ref_25","unstructured":"Food and Drug Administration (1996). FDA approves cidofovir for treatment of CMV retinitis. J. Int. Assoc. Physicians AIDS Care, 2, 30."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1086\/315190","article-title":"Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge","volume":"181","author":"Bray","year":"2000","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0166-3542(02)00196-1","article-title":"Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections","volume":"57","author":"Baker","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/AAC.00380-06","article-title":"Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype","volume":"50","author":"Kornbluth","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"Magee","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1399-3046.2008.00937.x","article-title":"Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy","volume":"12","author":"Araya","year":"2008","journal-title":"Pediatr. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antivir. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tibtech.2004.06.008","article-title":"Design and development of oral drugs for the prophylaxis and treatment of smallpox infection","volume":"22","author":"Painter","year":"2004","journal-title":"Trends Biotechnol."},{"key":"ref_34","unstructured":"Foster, S. (2010). Unpublished work."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.antiviral.2006.10.009","article-title":"Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice","volume":"73","author":"Hostetler","year":"2007","journal-title":"Antivir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ijantimicag.2003.10.010","article-title":"Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice","volume":"23","author":"Smee","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_39","unstructured":"Rao, A.R. (1972). Smallpox, The Kothari Book Depot."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/milmed\/167.7.546","article-title":"The cause of death in smallpox: An examination of the pathology record","volume":"167","author":"Martin","year":"2002","journal-title":"Mil. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"15196","DOI":"10.1073\/pnas.0405954101","article-title":"Exploring the potential of variola virus infection of cynomolgus macaques as a model for human smallpox","volume":"101","author":"Jahrling","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/sj.icb.7100033","article-title":"Immunopathogenesis of poxvirus infections: forecasting the impending storm","volume":"85","author":"Stanford","year":"2007","journal-title":"Immunol. Cell Biol."},{"key":"ref_43","first-page":"433","article-title":"Studies on the physiological disturbances occurring in experimental rabbit pox: an approach to rational therapy","volume":"42","author":"Boulter","year":"1961","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(61)90969-2","article-title":"Value of serotherapy in a virus disease (rabbit pox)","volume":"2","author":"Boulter","year":"1961","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0042-6822(81)90150-1","article-title":"Isolation and preliminary characterization of temperature-sensitive mutants of vaccinia virus","volume":"113","author":"Condit","year":"1981","journal-title":"Virology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0042-6822(83)90268-4","article-title":"Isolation, characterization, and physical mapping of temperature-sensitive mutants of vaccinia virus","volume":"128","author":"Condit","year":"1983","journal-title":"Virology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246 for Treatment of Poxvirus Infections","volume":"2","author":"Jordon","year":"2010","journal-title":"Viruses"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/3\/2\/63\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T21:55:02Z","timestamp":1760219702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/3\/2\/63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,25]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2011,2]]}},"alternative-id":["v3020063"],"URL":"https:\/\/doi.org\/10.3390\/v3020063","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,25]]}}}